Conclusions: Gemcitabine might represent a second-line treatment option after BCG failure in high-risk non-muscle- invasive BC patients.

The ability to significantly discriminate between superficial and invasive BC was observed only for hTR transcript levels.

Hazard ratios (HR) of developing invasive BC according to different levels of alcohol and fiber intake were computed.